Abstract |
A small library of integrin ligand- paclitaxel conjugates 10-13 was synthesized with the aim of using the tumor-homing cyclo[DKP-RGD] peptidomimetics for site-directed delivery of the cytotoxic drug. All the paclitaxel-RGD constructs 10-13 inhibited biotinylated vitronectin binding to the purified αVβ3 integrin receptor at low nanomolar concentration and showed in vitro cytotoxic activity against a panel of human tumor cell lines similar to that of paclitaxel. Among the cell lines, the cisplatin-resistant IGROV-1/Pt1 cells expressed high levels of integrin αVβ3, making them attractive to be tested in in vivo models. cyclo[DKP-f3-RGD]-PTX 11 displayed sufficient stability in physiological solution and in both human and murine plasma to be a good candidate for in vivo testing. In tumor-targeting experiments against the IGROV-1/Pt1 human ovarian carcinoma xenotransplanted in nude mice, compound 11 exhibited a superior activity compared with paclitaxel, despite the lower (about half) molar dosage used.
|
Authors | Raffaele Colombo, Michele Mingozzi, Laura Belvisi, Daniela Arosio, Umberto Piarulli, Nives Carenini, Paola Perego, Nadia Zaffaroni, Michelandrea De Cesare, Vittoria Castiglioni, Eugenio Scanziani, Cesare Gennari |
Journal | Journal of medicinal chemistry
(J Med Chem)
Vol. 55
Issue 23
Pg. 10460-74
(Dec 13 2012)
ISSN: 1520-4804 [Electronic] United States |
PMID | 23140358
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Integrin alphaVbeta3
- Oligopeptides
- Peptidomimetics
- arginyl-glycyl-aspartic acid
- Paclitaxel
|
Topics |
- Animals
- Antineoplastic Agents, Phytogenic
(chemistry, pharmacology)
- Cell Line, Tumor
- Female
- Humans
- Immunohistochemistry
- In Vitro Techniques
- Integrin alphaVbeta3
(drug effects)
- Magnetic Resonance Spectroscopy
- Male
- Oligopeptides
(chemistry, pharmacology)
- Paclitaxel
(chemistry, pharmacology)
- Peptidomimetics
- Spectrometry, Mass, Electrospray Ionization
|